- Poster presentation
- Open Access
Promoter methylation of PTEN gene in high grade gliomas
© Lavanya et al; licensee BioMed Central Ltd. 2014
- Published: 21 January 2014
- Methylation Status
- High Grade Glioma
- Central Nervous System Tumor
- Malignant Brain Tumor
- PI3K Signaling
Gliomas are the most common primary malignant central nervous system tumors arising from glial cells accounting for 80% of all malignant brain tumors. Many mutations occur frequently in genes that control cell cycle and proliferation leading to tumor progression. Major genes that are associated with the malignant tumors are MGMT, hTERT, TP53, PTEN, P16. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a tumor suppressor gene deleted or mutated in many cancers. It plays a significant role in cellular processes like cell cycle progression, apoptosis, translation, growth, proliferation and migration by negatively controlling PI3/AKt pathway. Deregulation of PI3K signaling pathways proceed from genetic alterations in the PTEN gene on 10q23 at the level of mutation, LOH and methylation identified in 60% of glioblastoma. Recent reports show that absence of PTEN was associated with increased tumor malignancy in gliomas. This seems to have prognostic significance and accepted as independent prognostic factor. In this study 15 high grade glioma tissues were collected from neurosurgery department and confirmed as glioma histologically.
DNA was isolated using Qiagen kit and bisulphite DNA conversion was done by Qiagen Epitect. PCR was performed to check the methylation status in the promoter region of PTEN gene.
We noticed that around 50% of patients DNA show methylation in promoter region of PTEN gene when compared with healthy control DNA. We are looking at the response of these patients to chemotherapy and radiotherapy. We are also looking in to changes in the PI3/AKt signaling pathway.
There is a possibility of correlation between the methylation status and patients survival.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.